T cells localized to the androgen-deprived prostate are T H1 and T H17 biased

Prostate

Volumn 72, Issue 11, 2012, Pages 1239-1247

  Morse, Matthew D ^a,b   McNeel, Douglas G ^b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

castration; cytokine; inflammation; prostate; rat

Indexed keywords

CYTOKINE;

ADOPTIVE TRANSFER; ANDROGEN DEPRIVATION THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CASTRATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; FLOW CYTOMETRY; HISTOPATHOLOGY; IMMUNE RESPONSE; LYMPHOCYTIC INFILTRATION; MALE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROSTATE; PROSTATE INFILTRATING LYMPHOCYTE; PROTEIN EXPRESSION; RAT; T LYMPHOCYTE; TH1 CELL; TH17 CELL;

ANIMALS; MALE; MODELS, ANIMAL; ORCHIECTOMY; PROSTATE; RATS; RATS, INBRED LEW; TH1 CELLS; TH17 CELLS;

EID: 84862839959     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22476     Document Type: Article

References (33)

1. Siegel R, Ward E, Brawley O, Jemal A,. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61 (4): 212-236.
2. Huggins C, Hodges CV,. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol 2002; 168 (1): 9-12.
3. Kyprianou N, Isaacs JT,. Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology 1988; 122 (2): 552-562.
4. Buttyan R, Shabsigh A, Perlman H, Colombel M,. Regulation of apoptosis in the prostate gland by androgenic steroids. Trends Endocrinol Metab 1999; 10 (2): 47-54.
5. Bacher M, Rausch U, Goebel HW, Polzar B, Mannherz HG, Aumuller G,. Stromal and epithelial cells from rat ventral prostate during androgen deprivation and estrogen treatment-Regulation of transcription. Exp Clin Endocrinol 1993; 101 (2): 78-86.
6. Nastiuk KL, Krolewski JJ,. FLIP-ping out: Death receptor signaling in the prostate. Cancer Biol Ther 2008; 7 (8): 1171-1179.
7. Martikainen P, Kyprianou N, Isaacs JT,. Effect of transforming growth factor-beta 1 on proliferation and death of rat prostatic cells. Endocrinology 1990; 127 (6): 2963-2968.
8. Mercader M, Bodner BK, Moser MT, Kwon PS, Park ES, Manecke RG, Ellis TM, Wojcik EM, Yang D, Flanigan RC, Waters WB, Kast WM, Kwon ED,. T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci USA 2001; 98 (25): 14565-14570.
9. Roden AC, Moser MT, Tri SD, Mercader M, Kuntz SM, Dong H, Hurwitz AA, McKean DJ, Celis E, Leibovich BC, Allison JP, Kwon ED,. Augmentation of T cell levels and responses induced by androgen deprivation. J Immunol 2004; 173 (10): 6098-6108.
10. Gannon PO, Poisson AO, Delvoye N, Lapointe R, Mes-Masson AM, Saad F,. Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients. J Immunol Methods 2009; 348 (1-2): 9-17.
11. Akins EJ, Moore ML, Tang S, Willingham MC, Tooze JA, Dubey P,. In situ vaccination combined with androgen ablation and regulatory T-cell depletion reduces castration-resistant tumor burden in prostate-specific pten knockout mice. Cancer Res 2010; 70 (9): 3473-3482.
12. Sutherland JS, Goldberg GL, Hammett MV, Uldrich AP, Berzins SP, Heng TS, Blazar BR, Millar JL, Malin MA, Chidgey AP, Boyd RL,. Activation of thymic regeneration in mice and humans following androgen blockade. J Immunol 2005; 175 (4): 2741-2753.
13. Morse MD, McNeel DG,. Prostate cancer patients on androgen deprivation therapy develop persistent changes in adaptive immune responses. Hum Immunol 2010; 71 (5): 496-504.
14. Williams KM, Lucas PJ, Bare CV, Wang J, Chu YW, Tayler E, Kapoor V, Gress RE,. CCL25 increases thymopoiesis after androgen withdrawal. Blood 2008; 112 (8): 3255-3263.
15. Dalal M, Kim S, Voskuhl RR,. Testosterone therapy ameliorates experimental autoimmune encephalomyelitis and induces a T helper 2 bias in the autoantigen-specific T lymphocyte response. J Immunol 1997; 159 (1): 3-6.
16. Koh YT, Gray A, Higgins SA, Hubby B, Kast WM,. Androgen ablation augments prostate cancer vaccine immunogenicity only when applied after immunization. Prostate 2009; 69 (6): 571-584.
17. Penna G, Fibbi B, Maggi M, Adorini L,. Prostate autoimmunity: From experimental models to clinical counterparts. Expert Rev Clin Immunol 2009; 5 (5): 577-586.
18. Naslund MJ, Strandberg JD, Coffey DS,. The role of androgens and estrogens in the pathogenesis of experimental nonbacterial prostatitis. J Urol 1988; 140 (5): 1049-1053.
19. Stoker TE, Robinette CL, Cooper RL,. Perinatal exposure to estrogenic compounds and the subsequent effects on the prostate of the adult rat: evaluation of inflammation in the ventral and lateral lobes. Reprod Toxicol 1999; 13 (6): 463-472.
20. Harris MT, Feldberg RS, Lau KM, Lazarus NH, Cochrane DE,. Expression of proinflammatory genes during estrogen-induced inflammation of the rat prostate. Prostate 2000; 44 (1): 19-25.
21. Seethalakshmi L, Bala RS, Malhotra RK, Austin-Ritchie T, Miller-Graziano C, Menon M, Luber-Narod J,. 17 beta-estradiol induced prostatitis in the rat is an autoimmune disease. J Urol 1996; 156 (5): 1838-1842.
22. Drake CG,. Update on prostate cancer vaccines. Cancer J 2011; 17 (5): 294-299.
23. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF,. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363 (5): 411-422.
24. McNeel DG,. Prostate cancer immunotherapy. Curr Opin Urol 2007; 17 (3): 175-181.
25. Drake CG, Doody AD, Mihalyo MA, Huang CT, Kelleher E, Ravi S, Hipkiss EL, Flies DB, Kennedy EP, Long M, McGary PW, Coryell L, Nelson WG, Pardoll DM, Adler AJ,. Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell 2005; 7 (3): 239-249.
26. Schreiber RD, Old LJ, Smyth MJ,. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011; 331 (6024): 1565-1570.
27. Hsu DS, Kim MK, Balakumaran BS, Acharya CR, Anders CK, Clay T, Lyerly HK, Drake CG, Morse MA, Febbo PG,. Immune signatures predict prognosis in localized cancer. Cancer Invest 2010; 28 (7): 765-773.
28. Ruffell B, DeNardo DG, Affara NI, Coussens LM,. Lymphocytes in cancer development: Polarization towards pro-tumor immunity. Cytokine Growth Factor Rev 2010; 21 (1): 3-10.
29. Derhovanessian E, Adams V, Hahnel K, Groeger A, Pandha H, Ward S, Pawelec G,. Pretreatment frequency of circulating IL-17+ CD4+ T-cells, but not Tregs, correlates with clinical response to whole-cell vaccination in prostate cancer patients. Int J Cancer 2009; 125 (6): 1372-1379.
30. Sfanos KS, Bruno TC, Maris CH, Xu L, Thoburn CJ, DeMarzo AM, Meeker AK, Isaacs WB, Drake CG,. Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin Cancer Res 2008; 14 (11): 3254-3261.
31. Dong C,. TH17cells in development: An updated view of their molecular identity and genetic programming. Nat Rev Immunol 2008; 8 (5): 337-348.
32. Ammirante M, Luo JL, Grivennikov S, Nedospasov S, Karin M,. B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature 2010; 464 (7286): 302-305.
33. Sorrentino C, Musiani P, Pompa P, Cipollone G, Di Carlo E,. Androgen deprivation boosts prostatic infiltration of cytotoxic and regulatory T lymphocytes and has no effect on disease-free survival in prostate cancer patients. Clin Cancer Res 2010; 17 (6): 1571-1581.